Profile data is unavailable for this security.
About the company
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
- Revenue in USD (TTM)0.00
- Net income in USD-39.85m
- Incorporated2004
- Employees20.00
- LocationEledon Pharmaceuticals Inc19800 MACARTHUR BLVD., SUITE 250IRVINE 92612United StatesUSA
- Phone+1 (949) 238-8090
- Fax+1 (302) 655-5049
- Websitehttps://eledon.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DiaMedica Therapeutics Inc | 0.00 | -19.26m | 107.25m | 18.00 | -- | 2.31 | -- | -- | -0.5532 | -0.5532 | 0.00 | 1.22 | 0.00 | -- | -- | 0.00 | -48.47 | -45.38 | -52.02 | -48.24 | -- | -- | -- | -- | -- | -- | 0.00006 | -- | -- | -- | -41.72 | -- | -13.65 | -- |
PMV Pharmaceuticals Inc | 0.00 | -65.10m | 109.06m | 63.00 | -- | 0.5128 | -- | -- | -1.32 | -1.32 | 0.00 | 4.13 | 0.00 | -- | -- | 0.00 | -26.53 | -21.16 | -27.81 | -21.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.94 | -- | 16.31 | -- |
Bioatla Inc | 0.00 | -119.24m | 109.70m | 65.00 | -- | 2.21 | -- | -- | -2.49 | -2.49 | 0.00 | 1.03 | 0.00 | -- | -- | 0.00 | -81.18 | -48.72 | -96.07 | -57.35 | -- | -- | -- | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
Yubo International Biotech Ltd | 604.68k | -1.20m | 111.43m | 18.00 | -- | -- | -- | 184.28 | -0.01 | -0.01 | 0.005 | -0.0154 | 0.3012 | 0.6912 | 9.19 | 33,593.33 | -59.52 | -- | -- | -- | 69.32 | -- | -197.64 | -- | 0.1504 | -3,143.97 | -- | -- | 479.86 | -- | 0.8224 | -- | -- | -- |
Rezolute Inc | 0.00 | -58.21m | 112.76m | 51.00 | -- | 1.59 | -- | -- | -1.14 | -1.14 | 0.00 | 1.77 | 0.00 | -- | -- | 0.00 | -52.46 | -58.48 | -55.28 | -63.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.13 | -- | 92.29 | -- |
Immunic Inc | 0.00 | -97.92m | 114.40m | 77.00 | -- | 1.37 | -- | -- | -1.84 | -1.84 | 0.00 | 0.9278 | 0.00 | -- | -- | 0.00 | -91.94 | -72.09 | -110.91 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
Cellectar Biosciences Inc | 0.00 | -50.98m | 114.72m | 20.00 | -- | 11.68 | -- | -- | -3.17 | -3.17 | 0.00 | 0.789 | 0.00 | -- | -- | 0.00 | -176.58 | -83.69 | -295.36 | -99.80 | -- | -- | -- | -- | -- | -4.81 | 0.00 | -- | -- | -- | -32.80 | -- | 17.55 | -- |
Vistagen Therapeutics Inc | 1.04m | -32.07m | 115.13m | 37.00 | -- | 0.9338 | -- | 110.46 | -3.56 | -3.56 | 0.0775 | 4.56 | 0.013 | -- | -- | 31,584.85 | -39.89 | -77.80 | -42.10 | -85.00 | -- | -- | -3,076.62 | -8,640.25 | -- | -- | 0.00006 | -- | -120.50 | -- | -21.64 | -- | 165.73 | -- |
Eledon Pharmaceuticals Inc | 0.00 | -39.85m | 115.13m | 20.00 | -- | 0.9916 | -- | -- | -1.41 | -1.41 | 0.00 | 3.02 | 0.00 | -- | -- | 0.00 | -48.86 | -38.44 | -51.95 | -39.80 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 54.16 | -- | -- | -- |
Vor Biopharma Inc | 0.00 | -120.23m | 117.07m | 168.00 | -- | 0.9509 | -- | -- | -1.78 | -1.78 | 0.00 | 1.80 | 0.00 | -- | -- | 0.00 | -54.09 | -45.79 | -57.42 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
Coya Therapeutics Inc | 6.13m | -10.30m | 118.55m | 8.00 | -- | 3.66 | -- | 19.34 | -0.8899 | -0.8899 | 0.5401 | 2.22 | 0.2236 | -- | -- | 766,131.30 | -37.59 | -- | -41.86 | -- | -- | -- | -168.11 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
Allakos Inc | 0.00 | -214.44m | 120.42m | 131.00 | -- | 1.15 | -- | -- | -2.45 | -2.45 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -81.27 | -42.71 | -92.78 | -45.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 41.96 | -- | -38.89 | -- |
FibroGen Inc | 167.49m | -240.46m | 122.35m | 486.00 | -- | -- | -- | 0.7305 | -2.45 | -2.45 | 1.70 | -2.29 | 0.3704 | 1.18 | 5.05 | 344,635.80 | -53.71 | -30.62 | -124.24 | -42.31 | 75.46 | 93.52 | -145.02 | -119.08 | 1.27 | -36.51 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
Nuvectis Pharma Inc | 0.00 | -22.38m | 122.43m | 13.00 | -- | 8.73 | -- | -- | -1.40 | -1.40 | 0.00 | 0.7639 | 0.00 | -- | -- | 0.00 | -124.61 | -- | -170.23 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.64 | -- | -- | -- |
Omega Therapeutics Inc | 4.94m | -92.28m | 123.00m | 93.00 | -- | 2.97 | -- | 24.90 | -1.67 | -1.67 | 0.0896 | 0.7498 | 0.029 | -- | 6.08 | 53,107.53 | -54.28 | -- | -62.10 | -- | -- | -- | -1,868.35 | -- | -- | -- | 0.302 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
BVF Partners LPas of 09 May 2024 | 3.36m | 13.89% |
Armistice Capital LLCas of 31 Mar 2024 | 2.30m | 9.49% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 969.12k | 4.01% |
Woodline Partners LPas of 31 Mar 2024 | 651.94k | 2.69% |
Ensign Peak Advisors, Inc.as of 31 Mar 2024 | 443.00k | 1.83% |
Geode Capital Management LLCas of 31 Mar 2024 | 180.90k | 0.75% |
CM Management LLCas of 31 Mar 2024 | 160.00k | 0.66% |
Susquehanna Financial Group LLLPas of 31 Mar 2024 | 99.78k | 0.41% |
Next Edge Capital Corp.as of 31 Dec 2023 | 90.00k | 0.37% |
Renaissance Technologies LLCas of 31 Mar 2024 | 87.07k | 0.36% |